

# STUDIENÜBERSICHT

Einige ausgewählte Studien entnehmen Sie bitte der folgenden Tabelle:

Autor	Jahr	Obsti- pation	Reiz- darm	Diar- rhö	CED	Aller- gien	Immun- funktion	Krebs
Aso Y	1992							X
Aso Y	1995							X
Koebnick C	2003	X						
De Preter V	2004							X
Ishikawa H	2005							X
Matsumoto S	2005				X			
Morimoto K	2005						X	
Matsumoto K	2006	X						
Fujimori S	2007				X			
Takeda K	2007						X	
Barrett JS	2008		X					
Gleeson M	2008						X	
Ivory K	2008					X		
Mitsuyama K	2008				X			
Shida K	2008						X	
Stockenhuber A	2008			X				
Lewis JDN	2009			X				
Staab B	2009						X	
Yamada T	2009			X				
Matsumoto K	2010		X					
Sur D	2010			X				
Gleeson M	2011						X	
Krammer Hj	2011	X						
Reale M	2011						X	
Snel J	2011					X		
Pirker A	2012			X				
Dong H	2013						X	
Wong S	2014			X				

Gerne lassen wir Ihnen kostenfrei die Originalpublikationen zu den oben genannten Studien oder Studien zu anderen Indikationen zukommen. Richten Sie Ihre Anfrage mit Postadresse einfach an [wissenschaft@yakult.de](mailto:wissenschaft@yakult.de).

# LITERATUR

- Andresen V et al. (2013).** S2k-Leitlinie Chronische Obstipation: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterologie 51: 651-672, [www.dgvs.de](http://www.dgvs.de)
- Aso Y et al. (1995).** Preventive effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 27: 104–109
- Bischoff SF, Köchling K (2012).** Pro- und Präbiotika. Aktuelle Ernährungsmed. 37: 287-306
- De Preter V et al. (2007).** Effect of dietary intervention with different pre- and probiotics on intestinal bacterial enzyme activities. Eur J Clin Nutr 62: 225–231
- De Preter V et al. (2004).** The in vivo use of the stable isotope-labelled biomarkers lactose-[15N]ureide and [2H4]tyrosine to assess the effects of pro- and prebiotics on the intestinal flora of healthy human volunteers. Br J Nutr 92: 439–446
- Dong H et al. (2013).** Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers. Eur J Nutr 52: 1853–1863
- Gleeson M et al. (2011).** Daily Probiotic's (*Lactobacillus casei* Shirota) Reduction of Infection Incidence in Athletes. Int J Sport Nutr Exerc Metab 21: 55–64
- Hao Q et al. (2011).** Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Syst Rev 9
- Hempel S et al. (2012).** Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea. A Systematic Review and Meta-analysis. Journal of the American Medical Association 307: 1959–1969
- Ishikawa H et al. (2005).** Randomized trial of dietary fiber and *Lactobacillus casei* administration for prevention of colorectal tumors. Int J Cancer 116: 762–767
- Ivory K et al. (2008).** Oral delivery of *Lactobacillus casei* Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy 38: 1282–9
- Koebnick C et al. (2003).** Probiotic beverage containing *Lactobacillus casei* Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastro 17: 655–659
- Krammer HJ et al. (2011).** Effect of *Lactobacillus casei* Shirota on colonic transit time in patients with chronic constipation. Coloproctology 33: 109–113
- Layer P et al. (2011).** S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Z Gastroenterol 49: 237–293
- Matsumoto K et al. (2006).** The Effects of a probiotic milk product containing *Lactobacillus casei* strain Shirota on the defecation frequency and the intestinal microflora of sub-optimal health state volunteers: a randomized placebo-controlled cross-over study. Biosc Microflora 25: 39–48
- Morimoto K et al. (2005).** Modulation of natural killer cell activity by supplementation of fermented milk containing *Lactobacillus casei* in habitual smokers. Prev Medicine 40, 589–594, 2005
- Ohashi Y et al. (2002).** Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 68: 273–80
- Pelucchi C, et al. (2012).** Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology 23 (3): 402-14
- Pirker A et al. (2012).** Effects of antibiotic therapy on the gastrointestinal microbiota and the influence of *Lactobacillus casei*. Food and Agricultural Immunology. DOI:10.1080/09540105.2012.689816
- Reale M et al. (2011).** Daily intake of *Lactobacillus casei* Shirota increases natural killer cell activity in smokers. British Journal of Nutrition 108: 308–314
- Shida K et al. (2002).** *Lactobacillus casei* strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin Experimental Allergy 32: 563–570
- Sugita T et al. (1994).** Efficacy of *Lactobacillus* preparation Biolactis powder in children with rotavirus enteritis. Jpn J Pediatr 47: 2755–2762
- Stockenhuber A et al. (2008).** Preventing antibiotic associated diarrhea using a probiotic *Lactobacillus casei* preparation. Gut 57 Suppl II: A20
- Takeda K et al. (2007).** Effects of a fermented milk drink containing *Lactobacillus casei* strain Shirota on the human NK-cell activity. J Nutr 137: 791S–3S
- Wong S et al. (2014).** A *Lactobacillus casei* Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Br J Nutr 111: 672–678